Survival benefits of human papillomavirus 16 infection in patients with esophageal squamous cell carcinoma undergoing chemoradiotherapy: A retrospective cohort study

Fengyi Qu,Chao Ji,Ying Wang,Rui Zhu,Weibin Hu,Siqi Liu,Xu Zhao,Jing Li,Guo Miao,Mingxin Zhang,Xiaozhi Zhang,Yuchen Sun
DOI: https://doi.org/10.1002/jmv.29592
IF: 20.693
2024-04-10
Journal of Medical Virology
Abstract:The role of human papillomavirus 16 (HPV 16) in esophageal squamous cell carcinoma (ESCC) remains uncertain. Therefore, this study aimed to investigate the prevalence of HPV 16 in patients with ESCC and its impact on theirprognosis. HPV 16 was detected using FISH, and TP53 status was evaluated via immunohistochemistry. The factors influencing prognosis were ananalyzed using the Log‐rank test and Cox regression analyses. Among 178 patients with ESCC, 105 and 73 patients were categorized into concurrent chemoradiotherapy (CCRT) and postoperative chemoradiotherapy (POCRT) cohorts, respectively. Among 178 patients, 87 (48.87%) tested positive for HPV 16. Log‐rank tests revealed that the overall survival (OS) of patients with ESCC who were HPV 16‐positive was longer than that of those who were HPV 16‐negative (median OS: 57 months vs. 27 months, p
virology
What problem does this paper attempt to address?